166 related articles for article (PubMed ID: 36112263)
1. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation.
Li S; He J; Liao X; He Y; Chen R; Chen J; Hu S; Sun J
Cell Biol Toxicol; 2023 Aug; 39(4):1641-1655. PubMed ID: 36112263
[TBL] [Abstract][Full Text] [Related]
2. SCF
Bai J; Wu K; Cao MH; Yang Y; Pan Y; Liu H; He Y; Itahana Y; Huang L; Zheng JN; Pan ZQ
Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11754-11763. PubMed ID: 31138683
[TBL] [Abstract][Full Text] [Related]
3. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
4. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
[TBL] [Abstract][Full Text] [Related]
5. FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
Johmura Y; Harris AS; Ohta T; Nakanishi M
Cancer Sci; 2020 Aug; 111(8):2718-2725. PubMed ID: 32536008
[TBL] [Abstract][Full Text] [Related]
6. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
[TBL] [Abstract][Full Text] [Related]
7. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
[TBL] [Abstract][Full Text] [Related]
8. Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis.
Liu P; Cong X; Liao S; Jia X; Wang X; Dai W; Zhai L; Zhao L; Ji J; Ni D; Liu Z; Chen Y; Pan L; Liu W; Zhang J; Huang M; Liu B; Tan M
Cell Death Differ; 2022 Jan; 29(1):1-13. PubMed ID: 34215846
[TBL] [Abstract][Full Text] [Related]
9. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.
Johmura Y; Sun J; Kitagawa K; Nakanishi K; Kuno T; Naiki-Ito A; Sawada Y; Miyamoto T; Okabe A; Aburatani H; Li S; Miyoshi I; Takahashi S; Kitagawa M; Nakanishi M
Nat Commun; 2016 Feb; 7():10574. PubMed ID: 26868148
[TBL] [Abstract][Full Text] [Related]
10. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
Tan MK; Lim HJ; Harper JW
Mol Cell Biol; 2011 Sep; 31(18):3687-99. PubMed ID: 21768309
[TBL] [Abstract][Full Text] [Related]
11. Fbxo22 promotes cervical cancer progression via targeting p57
Lin M; Zhang J; Bouamar H; Wang Z; Sun LZ; Zhu X
Cell Death Dis; 2022 Sep; 13(9):805. PubMed ID: 36127346
[TBL] [Abstract][Full Text] [Related]
12. FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.
Ma J; Wu Y; Cheng S; Yang W; Zhong L; Li Q; Fang L
Dig Dis Sci; 2023 May; 68(5):1913-1922. PubMed ID: 36515852
[TBL] [Abstract][Full Text] [Related]
13. FBXO22 inhibits proliferation and metastasis of cervical cancer cells by mediating ubiquitination-dependent degradation of GAK.
Li S; Shi L; Wang Y; Zhang L; Chu S; Li M; Bai J; Zhu W
Exp Cell Res; 2023 Sep; 430(1):113719. PubMed ID: 37442264
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
De S; Holvey-Bates EG; Mahen K; Willard B; Stark GR
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34795058
[TBL] [Abstract][Full Text] [Related]
15. FBXO22 protein is required for optimal synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine.
Dikopoltsev E; Foltyn VN; Zehl M; Jensen ON; Mori H; Radzishevsky I; Wolosker H
J Biol Chem; 2014 Dec; 289(49):33904-15. PubMed ID: 25336657
[TBL] [Abstract][Full Text] [Related]
16. Histone demethylase KDM5A regulates the ZMYND8-NuRD chromatin remodeler to promote DNA repair.
Gong F; Clouaire T; Aguirrebengoa M; Legube G; Miller KM
J Cell Biol; 2017 Jul; 216(7):1959-1974. PubMed ID: 28572115
[TBL] [Abstract][Full Text] [Related]
17. FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression.
Sun R; Xie HY; Qian JX; Huang YN; Yang F; Zhang FL; Shao ZM; Li DQ
Cancer Res; 2018 Sep; 78(18):5274-5286. PubMed ID: 29945959
[TBL] [Abstract][Full Text] [Related]
18. F-Box Protein FBXO22 Mediates Polyubiquitination and Degradation of CD147 to Reverse Cisplatin Resistance of Tumor Cells.
Wu B; Liu ZY; Cui J; Yang XM; Jing L; Zhou Y; Chen ZN; Jiang JL
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117675
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway.
Zheng Y; Chen H; Zhao Y; Zhang X; Liu J; Pan Y; Bai J; Zhang H
Invest New Drugs; 2020 Feb; 38(1):20-28. PubMed ID: 30887251
[TBL] [Abstract][Full Text] [Related]
20. FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.
Guo F; Liu J; Han X; Zhang X; Lin T; Wang Y; Bai J; Han J
Int J Biol Sci; 2019; 15(3):647-656. PubMed ID: 30745851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
